Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-994 in Narcolepsy Type 1 and 2
NCT04096560Phase 2Terminated
- Sponsor
- Takeda
- Start
- May 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of firazorexton in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), sponsored by Takeda. Started May 2020; status: terminated.
02
Drugs
firazorexton
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)
Beyond the preview
Go deeper on NCT04096560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04096560.